Special Encore: U.S. Pharmaceuticals - The Fu...

Our CIO and Chief U.S. Equity Strategist Mike Wilson reacts to Kevin Warsh’s first Fed meeting, explaining why the new chair’s credibility may require letting markets experience some short-term pain.Read more insights from Morgan Stanley.----- Transcript -----Welcome to Thoughts ...  Show more

As AI investment keeps growing, our strategists Carolyn Campbell and Vishwas Patkar discuss the many ways tech infrastructure gets financed and the opportunities for investors.Read more insights from Morgan Stanley.----- Transcript -----Carolyn Campbell: Welcome to Thoughts on th ...  Show more

with Andrew Lo (@AndrewWLo) and Jorge Conde (@JorgeCondeBio)

The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, M ...

Mapping the human genome led to big advances in diagnosing rare disease. But diagnosis is only the first step in dealing with an illness. So what do you do if your child is found to have a condition that has no treatment? We hear from Michelle Teng, a mother who co-founded a biot ...  Show more

with Vas Narasimhan (@vasnarasimhan), Jorge Conde (@jorgecondebio), Vijay Pande (@vijaypande), and Sonal Chokshi (@smc90)

On average, only 1 out of 20 medicines works when we actually bring them into the human body, and these rates of success haven't moved much in the ph ...

Speaking with the CEO and founder of a pharmaceutical company was an incredible experience. William Stilley knows the science inside and out. And, he is able to explain it clearly, in understandable terms. What makes Adial different from many of the well-known drug companies is t ...  Show more